Acalabrutinib demonstrates a favorable cardiovascular safety profile in CLL, with low cardiac failure rates compared to ibrutinib and chemoimmunotherapy. The selectivity of acalabrutinib reduces ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. This medicine is new or being used differently. Please report side ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback